Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral pexiganan adjunctive crossover trial in mild to moderate ulcerative colitis
IRCT20190924044863N6Phase 2Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pexiganan in autoimmune colitis (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Adverse events, Vital signs and 9 more. Started Oct 2026; status: recruiting.
02
Drugs
pexiganan
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on IRCT20190924044863N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190924044863N6.